After five successful years of anticancer drug discovery activities, the NCI will renew the NExT CBC. The Request for Proposals has been issued to identify centers to participate in the second version of the CBC.
To obtain a copy of the Request for Proposals, click here.
Details about the RFP are available at
Questions about the RFP? Send requests for clarifications to email@example.com by 5 PM EDT Wednesday, September 16, 2015.
Two Teleconferences for Bidders have been arranged to address submitted questions and any additional questions.
September 24, 2015, 2:00 - 3:00 p.m. EDT
October 15, 2015, 2:00 - 3:00 p.m. EDT
Dial in number: 855-462-5367 (U.S. and Canada)
Dial in number: 804-451-4138 (International)
If you have additional questions about the
renewal process, please contact
As the Nation’s agency responsible for leading the fight against cancer, the National Cancer Institute (NCI) launched the Chemical Biology Consortium in 2009 to translate promising discoveries and bring improved therapies to cancer patients.
The Chemical Biology Consortium (CBC) is the drug discovery engine of the NExT Program and consists of a network of Centers from academia, government and industry. The Consortium provides access to a broad range of scientific expertise and technical capabilities to support multidisciplinary drug discovery from target validation through clinical candidate selection.
By renewing the CBC Program, the NCI will proceed to identify Centers with scientific excellence and rigor essential for successful drug discovery. NCI’s Operations and Technical Support Prime Contractor, Leidos Biomedical Research, Inc., will soon issue a Request for Proposals (RFP). Responses are anticipated from academic, non-profit, and private institutions, small biotech concerns, and service providers (CROs). Interested applicants with technical and scientific expertise to support early drug discovery activities and/or specialized technologies essential for modern drug discovery efforts (e.g. structural biology and fragment based design, biophysical technologies, high content screening, metabolite or epigenetic analyses) are encouraged to apply.
Who: Researchers in academia, government, and industry. A list of highly ranked applications can be found Here.
What: Drug discovery and development projects focused on unmet needs that are not adequately addressed by the private sector. The NCI is committed to moving high-priority projects through to proof-of-concept clinical trials. For more information, visit About NExT.
What NExT is not: NExT is not a grant or contract mechanism. Rather, approved projects will be provided access to the Institute's drug discovery and preclinical and clinical development resources.
How: Entry into NExT can occur at any stage of the drug discovery or development pipeline, but depends on favorable review of the application's scientific merit. For more information, visit How to Apply. Approved discovery activities may be performed by the NCI Chemical Biology Consortium, the discovery component of NExT.
When: Submission Deadlines occur three times per year.
Where: Online submission of NExT Application.
Sponsors: NCI's Division of Cancer Treatment and Diagnosis and Center for Cancer Research.